Study progression on mechanism of long non-coding RNAs regulating drug resistance in osteosarcoma

doi:10.3760/cma.j.cn371439-20221005-00010

Abstract

Abstract:

Osteosarcoma is the most common primary solid bone malignancy. The main factor leading to recurrence and metastasis of osteosarcoma is resistance to chemotherapy drugs. Long non-coding RNAs can affect drug resistance in osteosarcoma by regulating epithelial-mesenchymal transition， cell autophagy， apoptosis， drug efflux， and cell cycle， suggesting that long non-coding RNAs may become new targets for drug resistance in osteosarcoma treatment.

Key words: RNA， long non-coding, Osteosarcoma, Drug resistance， neoplasms

Ma Xiaoping, Chang Junli, Sun Xingyuan, Yang Yanping. Study progression on mechanism of long non-coding RNAs regulating drug resistance in osteosarcoma[J]. Journal of International Oncology, 2023, 50(1): 51-54.

References 31

[1]	Wu W, Jing D, Meng Z, et al. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity[J]. Theranostics, 2020, 10(6): 2859-2871. DOI: 10.7150/thno.41279. doi: 10.7150/thno.41279 pmid: 32194840
[2]	Davis LE, Janeway KA, Weiss AR, et al. Clinical trial enrollment of adolescents and young adults with sarcoma[J]. Cancer, 2017, 123(18): 3434-3440. DOI: 10.1002/cncr.30757. doi: 10.1002/cncr.30757 pmid: 28493547
[3]	Li Z, Li X, Xu D, et al. An update on the roles of circular RNAs in osteosarcoma[J]. Cell Prolif, 2021, 54(1): e12936. DOI: 10.1111/cpr.12936. doi: 10.1111/cpr.12936
[4]	Sasaki R, Osaki M, Okada F. MicroRNA-based diagnosis and treatment of metastatic human osteosarcoma[J]. Cancers (Basel). 2019, 11(4): 553. DOI: 10.3390/cancers11040553. doi: 10.3390/cancers11040553
[5]	Gill J, Gorlick R. Advancing therapy for osteosarcoma[J]. Nat Rev Clin Oncol, 2021, 18(10): 609-624. DOI: 10.1038/s41571-021-00519-8. doi: 10.1038/s41571-021-00519-8 pmid: 34131316
[6]	张俊鹏, 于燕燕, 李宝生. lncRNA、circRNA调控食管鳞状细胞癌放化疗敏感性的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 185-189. DOI: 10.3760/cma.j.cn371439-20220104-00032. doi: 10.3760/cma.j.cn371439-20220104-00032
[7]	Qian X, Zhao J, Yeung PY, et al. Revealing lncRNA structures and interactions by sequencing-based approaches[J]. Trends Biochem Sci, 2019, 44(1): 33-52. DOI: 10.1016/j.tibs.2018.09.012. doi: S0968-0004(18)30197-X pmid: 30459069
[8]	Wang JY, Yang Y, Ma Y, et al. Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma[J]. Biomed Pharmacother, 2020, 121: 109627. DOI: 10.1016/j.biopha.2019.109627. doi: 10.1016/j.biopha.2019.109627
[9]	Liu SJ, Dang HX, Lim DA, et al. Long noncoding RNAs in cancer metastasis[J]. Nat Rev Cancer, 2021, 21(7): 446-460. DOI: 10.1038/s41568-021-00353-1. doi: 10.1038/s41568-021-00353-1 pmid: 33953369
[10]	Noronha C, Ribeiro AS, Taipa R, et al. Cadherin expression and EMT: a focus on gliomas[J]. Biomedicines, 2021, 9(10): 1328. DOI: 10.3390/biomedicines9101328. doi: 10.3390/biomedicines9101328
[11]	Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3): 212-226. DOI: 10.1016/j.tcb.2018.12.001. doi: S0962-8924(18)30201-0 pmid: 30594349
[12]	Li R, Ruan Q, Zheng J, et al. LINC01116 promotes doxorubicin resistance in osteosarcoma by epigenetically silencing miR-424-5p and inducing epithelial-mesenchymal transition[J]. Front Pharmacol, 2021, 12: 632206. DOI: 10.3389/fphar.2021.632206. doi: 10.3389/fphar.2021.632206
[13]	Kun-Peng Z, Chun-Lin Z, Xiao-Long M, et al. Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells[J]. J Cell Physiol, 2019, 234(5): 6927-6939. DOI: 10.1002/jcp.27435. doi: 10.1002/jcp.27435 pmid: 30204936
[14]	Usman RM, Razzaq F, Akbar A, et al. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance[J]. Asia Pac J Clin Oncol, 2021, 17(3): 193-208. DOI: 10.1111/ajco.13449. doi: 10.1111/ajco.13449
[15]	Wang K, Du B, Xu B, et al. JMJD6-STAT3^Y705ph axis promotes autophagy in osteosarcoma cancer cells by regulating ATG[J]. Biofactors, 2020, 46(5): 839-848. DOI: 10.1002/biof.1614. doi: 10.1002/biof.1614
[16]	Zhu K, Yuan Y, Wen J, et al. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22[J]. Aging (Albany NY), 2020, 12(8): 6644-6666. DOI: 10.18632/aging.103004. doi: 10.18632/aging.103004
[17]	Zhang J, Rao D, Ma H, et al. LncRNA SNHG15 contributes to doxorubicin resistance of osteosarcoma cells through targeting the miR-381-3p/GFRA1 axis[J]. Open Life Sci, 2020, 15(1): 871-883. DOI: 10.1515/biol-2020-0086. doi: 10.1515/biol-2020-0086 pmid: 33817274
[18]	D'Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy[J]. Cell Biol Int, 2019, 43(6): 582-592. DOI: 10.1002/cbin.11137. doi: 10.1002/cbin.11137 pmid: 30958602
[19]	Zhou B, Li L, Li Y, et al. Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis[J]. Biomed Pharmacother, 2018, 106: 850-857. DOI: 10.1016/j.biopha.2018.07.003. doi: S0753-3322(18)32968-8 pmid: 30119255
[20]	Liu L, Wang S. Long non-coding RNA OIP5-AS1 knockdown enhances CDDP sensitivity in osteosarcoma via miR-377-3p/FosL2 axis[J]. Onco Targets Ther, 2020, 13: 3853-3866. DOI: 10.2147/OTT.S232918. doi: 10.2147/OTT.S232918
[21]	Hu Y, Yang Q, Wang L, et al. Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma[J]. Biosci Rep, 2018, 38(3): BSR20180375. DOI: 10.1042/BSR20180375. doi: 10.1042/BSR20180375
[22]	Haider T, Pandey V, Banjare N, et al. Drug resistance in cancer: mechanisms and tackling strategies[J]. Pharmacol Rep, 2020, 72(5): 1125-1151. DOI: 10.1007/s43440-020-00138-7. doi: 10.1007/s43440-020-00138-7
[23]	Wang JQ, Yang Y, Cai CY, et al. Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance[J]. Drug Resist Updat, 2021, 54: 100743. DOI: 10.1016/j.drup.2021.100743. doi: 10.1016/j.drup.2021.100743
[24]	Han Z, Shi L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis[J]. Biochem Biophys Res Commun, 2018, 495(1): 947-953. DOI: 10.1016/j.bbrc.2017.11.121. doi: 10.1016/j.bbrc.2017.11.121
[25]	Tang R, Zhang Z, Han W. CircLRRK1 targets miR-223-3p to inhibit the proliferation, migration and invasion of trophoblast cells by regulating the PI3K/Akt signaling pathway[J]. Placenta, 2021, 104: 110-118. DOI: 10.1016/j.placenta.2020.12.003. doi: 10.1016/j.placenta.2020.12.003 pmid: 33310596
[26]	Wang B, Cao C, Liu X, et al. BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/Akt/mTOR signalling pathway[J]. Cell Oncol, 2020, 43(2): 223-235. DOI: 10.1007/s13402-019-00482-8. doi: 10.1007/s13402-019-00482-8
[27]	Zhou B, Xiang J, Zhan C, et al. STK33 promotes the growth and progression of human pancreatic neuroendocrine tumour via activation of the PI3K/Akt/mTOR pathway[J]. Neuroendocrinology, 2020, 110(3-4): 307-320. DOI: 10.1159/000501829. doi: 10.1159/000501829 pmid: 31261148
[28]	Song L, Zhou Z, Gan Y, et al. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/Akt/mTOR signaling pathway by sponging the miR-340-5p[J]. J Cell Biochem, 2019, 120(6): 9656-9666. DOI: 10.1002/jcb.28244. doi: 10.1002/jcb.28244 pmid: 30548308
[29]	Sun ZY, Jian YK, Zhu HY, et al. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/Akt pathway[J]. Pathol Res Pract, 2019, 215(3): 555-563. DOI: 10.1016/j.prp.2018.12.013. doi: 10.1016/j.prp.2018.12.013
[30]	Zhang L, Zhao G, Ji S, et al. Downregulated long non-coding RNA MSC-AS1 inhibits osteosarcoma progression and increases sensitivity to cisplatin by binding to microRNA-142[J]. Med Sci Monit, 2020, 26: e921594. DOI: 10.12659/MSM.921594. doi: 10.12659/MSM.921594
[31]	Wang F, Kong L, Pu Y, et al. Long noncoding RNA DICER1-AS1 functions in methylation regulation on the multi-drugresistance of osteosarcoma cells via miR-34a-5p and GADD45A[J]. Front Oncol, 2021, 11: 685881. DOI: 10.3389/fonc.2021.685881. doi: 10.3389/fonc.2021.685881